The recent advent of anti-FGF23 antibody therapy in patients with XLH has enabled the effective treatment of hypophosphatemia, and anti-FGF23 therapy significantly improves the bone phenotype in patients with XLH (33, 34) and in Hyp mice (35). Here, FGF23 is linked to X-linked hypophosphatemia.